Purpose: To study a large family with X-linked progressive cone-rod dystrophy.
Methods: There were 128 members in the family. Of these, 45 had an ophthalmological examination and 3 gave their permission to use the results of their recent ophthalmological examination. In addition to the usual eye examination, visual fields, colour vision, dark adaptation and electroretinogram (ERG) were examined.
Results: Ten affected men aged 6 to 81 years were found in the family. The visual acuities varied from counting fingers (cf) 10 cm to 0.5 in the right eye (RE) and from cf 30 cm to 0.4 in the left eye (LE). The refraction was myopic in all affected members, varying from -1.5 to -24.0 D (RE) and from -2.0 to -20.25 D (LE). In visual functions, central scotomas and concentric constriction in the visual fields, red or red-green defects in colour vision, abnormal cone and rod dark adaptation and affected cone response in ERG were found. The 6 obligate carriers were aged 17 to 77 years. Their visual acuities varied from 0.05 (strabismic amblyopia) to 1.25(RE) and from 0.7 to 1.25 (LE), and refraction from +/-0 to +6.0 D (RE) and from -0.5 to +5.0 D (LE). Their visual fields and colour vision were normal. The non-affected men were aged 13 to 55 years, their visual acuity was normal in both eyes, and refraction varied from -5.0 to +1.5 D (RE) and from -5.5 to +1.75 (LE). The result of the eye examination was normal except in colour vision: two men were congenitally deuteranomalous. The women who were not obligate carriers were aged 10 to 77 years, their visual acuity was from 0.3 to 1.6 in both eyes, and refraction from -5.5 to +4.75 (RE) and from -5.25 to +4.0 (LE). Two women had one amblyopic eye. Otherwise the eye examination was normal.
Conclusions: The clinical diagnosis of X-linked cone dystrophy 1 (COD1) is based on progressive loss of visual acuity, moderate or high myopia, red colour vision defect and affected cone response or cone and rod response in ERG. The future identification of the COD1 gene will confirm the diagnosis of the disease and help in genetic counseling of the family.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1034/j.1600-0420.2001.079004359.x | DOI Listing |
Cureus
December 2024
Optometric - Glaucoma, Leicester Royal Infirmary, Leicester, GBR.
Colour vision defects (CVDs) can be both congenital and acquired, with acquired dyschromatopsia often associated with medication toxicity. This review explores various standardised colour vision tests used to detect these defects, including the Ishihara plate test, Farnsworth-Munsell 100 hue test, and anomaloscopes. These methods are evaluated for their effectiveness in diagnosing CVDs, particularly in acquired conditions.
View Article and Find Full Text PDFFront Bioeng Biotechnol
January 2025
Biomedical Engineering Department, College of Engineering, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Introduction: Color vision deficiency (CVD), a common visual impairment, affects individuals' ability to differentiate between various colors due to malfunctioning or absent color photoreceptors in the retina. Currently available diagnostic tests require a behavioral response, rendering them unsuitable for individuals with limited physical and communication abilities, such as those with locked-in syndrome. This study introduces a novel, non-invasive method that employs brain signals, specifically Steady-State Visually Evoked Potentials (SSVEPs), along with Ishihara plates to diagnose CVD.
View Article and Find Full Text PDFJ Cosmet Dermatol
January 2025
Department of Pharmaceutics, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Background: Doxepin (DX) is used orally to relieve itching but can cause side effects like blurred vision, dry mouth, and drowsiness due to its antimuscarinic effect. To reduce these adverse effects and improve skin permeation, DX is being developed in topical formulations. This study aims to improve DX skin absorption by developing a microemulsion (ME) formulation (ME-DX).
View Article and Find Full Text PDFJ Transl Med
January 2025
Department of Anesthesiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, People's Republic of China.
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, commonly causing sensory disturbances, motor weakness, impaired gait, incoordination and optic neuritis (ON). According to the statistics, up to 50% of MS patients experience vision problems during the disease course, suffering from blurred vision, pain, color vision deficits, and even blindness. Treatments have progressed from corticosteroids to therapies targeted against B/T cells.
View Article and Find Full Text PDFBMJ Open
January 2025
Lancaster Medical School, Lancaster University, Lancaster, UK.
Introduction: Congenital colour vision deficiency (CVD), known as colour blindness, is a common visual problem affecting around 1 in 12 men and 1 in 200 women. It is known that people who have red-green CVD, the most common phenotype, can have difficulty differentiating colours and this can impact the ability to perform clinical tasks related to patient care. The objective of this scoping review is to understand the extent and type of evidence and the impact on clinical practice and patient safety arising from congenital CVD in healthcare professionals.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!